Association of VEGF and VEGFR1 Polymorphisms with Breast Cancer Risk in North Indians

Overview

Journal Tumour Biol

Publisher Sage Publications

Specialty Oncology

Date 2015 Jan 22

PMID 25604142

Citations 11

Authors

Ruhi Kapahi

Kamlesh Guleria

Vasudha Sambyal

Mridu Manjari

Meena Sudan

Manjit Singh Uppal

Neeti Rajan Singh

Affiliations

Soon will be listed here.

Abstract

The aim of present study was to evaluate the relationship between vascular endothelial growth factor (VEGF) -2578C/A, -2549I/D, -460T/C and -7C/T and VEGFR1 -710C/T polymorphisms with risk to breast cancer in North Indians. A total of 204 sporadic breast cancer patients and 204 controls were recruited for this case-control study. Significantly increased frequency of II genotype of -2549I/D polymorphism was observed in patients as compared to control individuals (odds ratio (OR) = 2.76, 95 % confidence interval (CI), 1.55-4.92; p = 0.0005). VEGF -2578AA genotype (OR = 2.87; 95 % CI, 1.61-5.10; p = 0.0003) and A allele (OR = 1.65, 95 % CI, 1.25-2.18; p = 0.0004) were found to be associated with increased risk for breast cancer. Individuals carrying CC genotype (OR = 2.23, 95 % CI, 1.25-3.97) and C allele (OR = 1.42, 95 % CI, 1.07-1.87) of VEGF -460T/C polymorphism were at higher risk of breast cancer. There was no significant difference in genotype and allele distribution of VEGF -7C/T and VEGFR1 -710C/T polymorphisms between cases and control individuals (p > 0.05). Linkage disequilibrium analysis showed a strong linkage between VEGF -2549I/D and -2578C/A polymorphisms (Lewontin's [Formula: see text] = 0.99; r (2) = 0.97), -2549I/D and -460T/C ([Formula: see text] = 0.94; r (2) = 0.84), and -2578C/A and -460T/C polymorphisms ([Formula: see text] = 0.93; r (2) = 0.83). In the present study, we concluded that VEGF -2549I/D, -2578C/A and -460T/C polymorphisms are associated with risk to breast cancer in Punjab, North India.

Citing Articles

Receptor tyrosine kinases in breast cancer treatment: unraveling the potential.

Qi Y, Deng S, Wang K Am J Cancer Res. 2024; 14(9):4172-4196.

PMID: 39417188 PMC: 11477839. DOI: 10.62347/KIVS3169.

The rs3025039 Variant Is a Risk Factor for Breast Cancer in Mexican Women.

Gutierrez-Zepeda B, Gomez-Del Toro M, Ortiz-Soto D, Becerra-Loaiza D, Quiroz-Bolanos A, Topete A Int J Mol Sci. 2024; 25(18).

PMID: 39337657 PMC: 11432390. DOI: 10.3390/ijms251810172.

Association of -2549 I/D and +936 C/T Polymorphisms with Chronic Kidney Disease in North-West Indian Patients.

Tung G, Sambyal V, Guleria K Indian J Nephrol. 2022; 32(5):445-451.

PMID: 36568591 PMC: 9775598. DOI: 10.4103/ijn.ijn_420_21.

Impact of VEGFA promoter polymorphisms on esophageal cancer risk in North-West Indians: a case-control study.

Guleria K, Kaur S, Mahajan D, Sambyal V, Sudan M, Uppal M Genes Genomics. 2022; 44(8):923-936.

PMID: 35767183 DOI: 10.1007/s13258-022-01269-2.

Influence of polymorphisms in the gene on allograft rejection after kidney transplantation: a meta-analysis.

Eiamsitrakoon T, Tharabenjasin P, Pabalan N, Jarjanazi H, Tasanarong A F1000Res. 2022; 10:90.

PMID: 35284063 PMC: 8905004. DOI: 10.12688/f1000research.27800.1.

References

Konac E, Onen H, Metindir J, Alp E, Biri A, Ekmekci A . Lack of association between -460 C/T and 936 C/T of the vascular endothelial growth factor and angiopoietin-2 exon 4 G/A polymorphisms and ovarian, cervical, and endometrial cancers. DNA Cell Biol. 2007; 26(7):453-63. DOI: 10.1089/dna.2007.0585. View

Jin Q, Hemminki K, Enquist K, Lenner P, Grzybowska E, Klaes R . Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin Cancer Res. 2005; 11(10):3647-53. DOI: 10.1158/1078-0432.CCR-04-1803. View

Linderholm B, Lindh B, Tavelin B, Grankvist K, Henriksson R . p53 and vascular-endothelial-growth-factor (VEGF) expression predicts outcome in 833 patients with primary breast carcinoma. Int J Cancer. 2000; 89(1):51-62. View

Kjaer-Frifeldt S, Fredslund R, Lindebjerg J, Hansen T, Spindler K, Jakobsen A . Prognostic importance of VEGF-A haplotype combinations in a stage II colon cancer population. Pharmacogenomics. 2012; 13(7):763-70. DOI: 10.2217/pgs.12.38. View

Onen I, Konac E, Eroglu M, Guneri C, Biri H, Ekmekci A . No association between polymorphism in the vascular endothelial growth factor gene at position -460 and sporadic prostate cancer in the Turkish population. Mol Biol Rep. 2007; 35(1):17-22. DOI: 10.1007/s11033-006-9046-2. View

Benjamin L, Keshet E . Conditional switching of vascular endothelial growth factor (VEGF) expression in tumors: induction of endothelial cell shedding and regression of hemangioblastoma-like vessels by VEGF withdrawal. Proc Natl Acad Sci U S A. 1997; 94(16):8761-6. PMC: 23118. DOI: 10.1073/pnas.94.16.8761. View

Ke Q, Liang J, Wang L, Hu Z, Jin G, Zhou Y . Potentially functional polymorphisms of the vascular endothelial growth factor gene and risk of gastric cancer. Mol Carcinog. 2008; 47(8):647-51. DOI: 10.1002/mc.20435. View

Jacobs E, Feigelson H, Bain E, Brady K, Rodriguez C, Stevens V . Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006; 8(2):R22. PMC: 1557725. DOI: 10.1186/bcr1400. View

Pande D, Negi R, Khanna S, Khanna R, Khanna H . Vascular endothelial growth factor levels in relation to oxidative damage and antioxidant status in patients with breast cancer. J Breast Cancer. 2011; 14(3):181-4. PMC: 3200512. DOI: 10.4048/jbc.2011.14.3.181. View

10.

Willett C, Boucher Y, Tomaso E, Duda D, Munn L, Tong R . Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10(2):145-7. PMC: 2693485. DOI: 10.1038/nm988. View

11.

Hanahan D, Folkman J . Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell. 1996; 86(3):353-64. DOI: 10.1016/s0092-8674(00)80108-7. View

12.

He Y, Ni J, Chen S, Jiang Y, Jia S, Gao Y . The vascular endothelial growth factor-2549 insertion/deletion polymorphism is not associated with susceptibility to hepatocellular carcinoma in Chinese. DNA Cell Biol. 2010; 29(7):393-6. DOI: 10.1089/dna.2009.1015. View

13.

Shahbazi M, Fryer A, Pravica V, Brogan I, Ramsay H, Hutchinson I . Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J Am Soc Nephrol. 2001; 13(1):260-264. DOI: 10.1681/ASN.V131260. View

14.

Kamoun M, Houman M, Hamzaoui A, Hamzaoui K . Vascular endothelial growth factor gene polymorphisms and serum levels in Behçet's disease. Tissue Antigens. 2008; 72(6):581-7. DOI: 10.1111/j.1399-0039.2008.01145.x. View

15.

Vincenti V, CASSANO C, Rocchi M, Persico G . Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation. 1996; 93(8):1493-5. DOI: 10.1161/01.cir.93.8.1493. View

16.

Awata T, Inoue K, Kurihara S, Ohkubo T, Watanabe M, Inukai K . A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes. 2002; 51(5):1635-9. DOI: 10.2337/diabetes.51.5.1635. View

17.

Rodrigues P, Furriol J, Tormo E, Ballester S, Lluch A, Eroles P . The single-nucleotide polymorphisms +936 C/T VEGF and -710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res Treat. 2012; 133(2):769-78. DOI: 10.1007/s10549-012-1980-1. View

18.

Saenz-Lopez P, Vazquez F, Cozar J, Carretero R, Garrido F, Ruiz-Cabello F . VEGF polymorphisms are not associated with an increased risk of developing renal cell carcinoma in Spanish population. Hum Immunol. 2012; 74(1):98-103. DOI: 10.1016/j.humimm.2012.10.014. View

19.

Szeto C, Chow K, Poon P, Szeto C, Wong T, Kam-Tao Li P . Genetic polymorphism of VEGF: Impact on longitudinal change of peritoneal transport and survival of peritoneal dialysis patients. Kidney Int. 2004; 65(5):1947-55. DOI: 10.1111/j.1523-1755.2004.00605.x. View

20.

Hicklin D, Ellis L . Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol. 2004; 23(5):1011-27. DOI: 10.1200/JCO.2005.06.081. View